Microcap Ledger Celularity Inc $CELU
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Florham Park, NJ
- Fiscal year end
- December 31
- Shares outstanding
- 32,449,767 [10-Q 2026-09-29]
What the company doesAI summary of filing
Celularity Inc. is a cellular and regenerative medicine company developing off-the-shelf placental-derived allogeneic cellular therapies and advanced biomaterial products for age-related degenerative diseases. The company is clinical-stage for its cellular therapy candidates, including cenplacel-L (MLASCs) which has demonstrated data in Phase 1 and Phase 2 studies, while generating revenue from commercial-stage biomaterial products such as Biovance, Interfyl, and Rebound marketed for soft tissue repair and reconstructive procedures. Celularity also provides contract manufacturing and development services to third parties, and operates a biobanking service offering collection and cryogenic preservation of umbilical cord blood and placental tissue. The company manufactures products in its own 147,215 square foot cGMP-compliant facility in New Jersey. [10-K 2026-04-30]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 3 months to Mar 2026 | $3.85M | $874.0K | $1.45M | $368.0K | [10-Q 2026-09-29] |
| FY ended Dec 2025 | $26.55M | −$91.72M | −$13.25M | $6.17M | [10-K 2026-04-30] |
| FY ended Dec 2024 | $54.22M | −$57.89M | −$6.40M | $738.0K | [10-K 2026-04-30] |
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-12-02 | 22,484,239 | [10-Q 2024-12-06] |
| 2025-04-06 | 23,949,229 | [10-K 2025-05-08] |
| 2025-05-06 | 23,949,229 | [10-K/A 2025-05-21] |
| 2025-08-29 | 26,691,477 | [10-Q 2025-08-29] |
| 2025-08-30 | 26,691,477 | [10-Q 2025-08-29] |
| 2025-11-14 | 28,328,880 | [10-Q 2025-11-14] |
| 2026-04-28 | 28,945,961 | [10-K 2026-04-30] |
| 2026-09-24 | 32,449,767 | [10-Q 2026-09-29] |
- Shelf registration
- S-1 filed 2025-12-31; declared effective 2026-01-07 [S-1 2025-12-31]
Listing status
Current status: 5 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-07-29. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-07-29 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-07-29] |
| 2026-06-12 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-06-12] |
| 2025-04-23 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-04-23] |
| 2024-11-29 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2024-11-29] |
| 2024-10-21 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2024-10-21] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-04-13 | Brigido Stephen | exercise | 821 | — | [4 2026-04-15] |
| 2026-04-13 | Brigido Stephen | other | 268 | $1.28 | [4 2026-04-15] |
| 2026-04-13 | Haines John R | exercise | 1,641 | — | [4 2026-04-15] |
| 2026-04-13 | Haines John R | other | 583 | $1.28 | [4 2026-04-15] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-29 | 8-K | Director or officer change |
| 2026-09-29 | 10-Q | Quarterly report |
| 2026-09-28 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-09-28 | 8-K | Material agreement entered; New financial obligation; Unregistered sale of equity |
| 2026-09-14 | 8-K | Other events |
| 2026-08-14 | NT 10-Q | Notice of late quarterly report |
| 2026-08-07 | 8-K | Director or officer change |
| 2026-07-29 | 8-K | Listing notice or transfer |
| 2026-06-30 | 8-K | Material agreement entered; New financial obligation; Director or officer change |
| 2026-06-25 | 8-K | Director or officer change |
| 2026-06-23 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-06-12 | 8-K | Listing notice or transfer |
Alerts for $CELU
Email me when Celularity Inc files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.